<DOC>
	<DOCNO>NCT00676520</DOCNO>
	<brief_summary>XIENCE V USA prospective , multi-center , multi-cohort post-approval study . The objective study - To evaluate XIENCE V EECSS continue safety effectiveness commercial use real world setting , - To support Food Drug Administration ( FDA ) dual antiplatelet therapy ( DAPT ) initiative . This initiative design evaluate composite death , myocardial infarction ( MI ) stroke ( MACCE ) survival patient free Academic Research Consortium ( ARC ) definite probable stent thrombosis ( ST ) treat drug elute stent ( DES ) extend dual antiplatelet therapy .</brief_summary>
	<brief_title>XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study ( XIENCE V® USA-Phase 1 )</brief_title>
	<detailed_description>Study Phase I index procedure 1 year . This prospective , open-label , multi-center , observational , single-arm study design evaluate XIENCE V EECSS safety effectiveness real world setting 1 year implantation . The primary endpoint stent thrombosis ( definite probable ) rate 1 year ARC . The co-primary endpoint composite rate cardiac death MI 1 year . Up 8,000 patient plan consecutively enrol 275 site U.S. Clinical follow-up occur 14 , 30 , 180 day 1 year . All patient enrol XIENCE V USA complete Study Phase I evaluate 1 year determine whether eligible participate one follow cohort Study Phase II : XIENCE V USA Long Term Follow-up ( LTF ) Cohort , Harvard Clinical Research Institute ( HCRI ) DAPT Cohort , Abbott Vascular ( AV ) DAPT Cohort .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>The patient agree participate study sign Institutional Review Board approve inform consent form . The inability obtain informed consent . Age limit determine investigator . There angiographic inclusion exclusion criterion study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Angioplasty</keyword>
	<keyword>Coronary Restenosis</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Artery Restenosis</keyword>
	<keyword>Coronary Artery Stenosis</keyword>
	<keyword>Total Artery Occlusion</keyword>
	<keyword>Stents</keyword>
	<keyword>Stent Thrombosis</keyword>
	<keyword>Total Coronary Occlusion</keyword>
	<keyword>Vascular Disease</keyword>
	<keyword>Myocardial Ischemia</keyword>
</DOC>